$2.18
-0.41 (-15.83%)
Open$2.58
Previous Close$2.59
Day High$2.64
Day Low$2.13
52W High$2.70
52W Low$0.27
Volume—
Avg Volume208.1K
Market Cap137.83M
P/E Ratio—
EPS$-0.51
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+1,136.7% upside
Current
$2.18
$2.18
Target
$26.96
$26.96
$18.17
$26.96 avg
$35.46
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 68.45M | 35.55M | 33.75M |
| Net Income | -13,439,175 | 3.58M | 3.41M |
| Profit Margin | -19.6% | 10.1% | 10.1% |
| EBITDA | -14,905,588 | 5.92M | 5.34M |
| Free Cash Flow | — | 3.84M | 3.54M |
| Rev Growth | — | -9.4% | +19.8% |
| Debt/Equity | — | 0.12 | 0.13 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |